News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dynavax Technologies Corporation (DVAX) Reports Fourth Quarter And Year End 2013 Financial Results


3/11/2014 10:27:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERKELEY, CA--(Marketwired - March 10, 2014) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2013. The Company had $189.4 million in cash, cash equivalents and marketable securities as of December 31, 2013.

For the quarter ended December 31, 2013, Dynavax reported total revenues of $2.8 million compared to $1.8 million for the fourth quarter of 2012. For the year ended December 31, 2013, total revenues were $11.3 million compared to $9.7 million for 2012.

General and administrative expenses were $3.7 million for the quarter ended December 31, 2013 compared to $9.3 million for the fourth quarter of 2012. For the twelve months ended December 31, 2013, general and administrative expenses were $25.9 million compared to $28.2 million for the same period in 2012. The 2013 twelve month period includes non-recurring and non-cash stock-based severance costs of $7.7 million compared to $2.1 million for the same period in 2012. General and administrative expenses other than these organizational transition costs decreased by 38% during the fourth quarter and 28% for the twelve month period of 2013.

Research and development expenses were $12.1 million for the quarter ended December 31, 2013 compared to $12.5 million for the fourth quarter of 2012. For the twelve months ended December 31, 2013, research and development expenses were $50.9 million compared to $49.1 million for the same period in 2012.

The net loss allocable to common stockholders for the twelve months ended December 31, 2013 was $75.2 million, or $0.38 per basic and diluted share, which includes a one-time non-cash deemed dividend of $8.5 million related to the beneficial conversion feature of the Series B Convertible Preferred Stock. The net loss allocable to common stockholders for the twelve months ended December 31, 2012 was $69.9 million, or $0.41 per basic and diluted share.

About HEPLISAV

HEPLISAV is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response. Dynavax has worldwide commercial rights to HEPLISAV.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.

                                                                            
                      DYNAVAX TECHNOLOGIES CORPORATION                      
                    CONSOLIDATED STATEMENTS OF OPERATIONS                   
                  (In thousands, except per share amounts)                  
                                 (Unaudited)                                
                                                                            
                                  Three Months Ended        Years Ended     
                                     December 31,          December 31,     
                                 --------------------  -------------------- 
                                    2013       2012       2013       2012   
                                 ---------  ---------  ---------  --------- 
Revenues:                                                                   
  Collaboration revenue          $   1,580  $   1,008  $   4,929  $   4,610 
  Grant revenue                      1,283        751      5,138      3,939 
  Service and license revenue          (16)        47      1,184      1,165 
                                 ---------  ---------  ---------  --------- 
Total revenues                       2,847      1,806     11,251      9,714 
                                                                            
Operating expenses:                                                         
  Research and development          12,131     12,515     50,870     49,146 
  General and administrative         3,700      9,293     25,943     28,164 
  Unoccupied facility expense            8         --        926         -- 
                                 ---------  ---------  ---------  --------- 
Total operating expenses            15,839     21,808     77,739     77,310 
                                 ---------  ---------  ---------  --------- 
                                                                            
Loss from operations               (12,992)   (20,002)   (66,488)   (67,596)
                                                                            
Interest income                        (47)        83        116        291 
Interest expense                        83       (586)        --     (2,351)
Other income (expense)                (100)       (38)      (348)      (293)
                                 ---------  ---------  ---------  --------- 
                                                                            
Net loss                           (13,056)   (20,543)   (66,720)   (69,949)
                                 =========  =========  =========  ========= 
                                                                            
Preferred stock deemed dividend     (8,469)        --     (8,469)        -- 
                                                                            
Net loss allocable to common                                                
 stockholders                    $ (21,525) $ (20,543) $ (75,189) $ (69,949)
                                 =========  =========  =========  ========= 
                                                                            
Basic and diluted net loss per                                              
 share allocable to common                                                  
 stockholders                    $   (0.09) $   (0.11) $   (0.38) $   (0.41)
                                 =========  =========  =========  ========= 
                                                                            
Shares used to compute basic and                                            
 diluted net loss per share                                                 
 allocable to common                                                        
 stockholders                      235,879    180,685    196,275    170,469 
                                 =========  =========  =========  ========= 
                                                                            
                                                                            
                                                                            
                      DYNAVAX TECHNOLOGIES CORPORATION                      
                         SELECTED BALANCE SHEET DATA                        
                               (In thousands)                               
                                 (Unaudited)                                
                                                                            
                                                  December 31,  December 31,
                                                      2013          2012    
                                                 ------------- -------------
Assets                                                                      
  Cash, cash equivalents and marketable                                     
   securities                                    $     189,376 $     125,130
  Property and equipment, net                            8,706         7,965
  Goodwill                                               2,579         2,475
  Other assets                                           3,961         4,182
                                                 ------------- -------------
Total assets                                     $     204,622 $     139,752
                                                 ============= =============
                                                                            
Liabilities and stockholders' equity                                        
  Deferred revenues                              $       7,298 $      12,068
  Other liabilities                                     11,030        12,858
                                                 ------------- -------------
  Total liabilities                                     18,328        24,926
  Stockholders' equity                                 186,294       114,826
                                                 ------------- -------------
Total liabilities and stockholders' equity       $     204,622 $     139,752
                                                 ============= =============
                                                                            

Contact:
Michael Ostrach
Chief Business and Principal Financial Officer
510-665-7257
Email Contact



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES